MSL Pharma Ltd. (Met Syn Lysine)

MSL Pharma Ltd. (Met Syn Lysine) focuses on ideation, analysis, and identifying pathological pathways to treat diseases. The company develops novel peptidomimetics for treating obesity and metabolic syndrome (from a pre-diabetic state to type 2 diabetes, dyslipidemia, hypertension). They also have technologies to synthesize novel peptides for peptide-drug conjugates (PDCs) to diagnose and treat different tumors. The company aims to improve and prolong people's lives, reduce morbidity and mortality by relying on evidence-based medicine, analyzing science, and innovating.